Product Name :
ZSET-845
Description:
ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat.
CAS:
324077-62-5
Molecular Weight:
314.38
Formula:
C21H18N2O
Chemical Name:
3,3-dibenzyl-2H,3H-imidazo[1,2-a]pyridin-2-one
Smiles :
O=C1N=C2C=CC=CN2C1(CC1C=CC=CC=1)CC1C=CC=CC=1
InChiKey:
AGKKYNURMHHCFP-UHFFFAOYSA-N
InChi :
InChI=1S/C21H18N2O/c24-20-21(15-17-9-3-1-4-10-17,16-18-11-5-2-6-12-18)23-14-8-7-13-19(23)22-20/h1-14H,15-16H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat.|Product information|CAS Number: 324077-62-5|Molecular Weight: 314.38|Formula: C21H18N2O|Chemical Name: 3,3-dibenzyl-2H,3H-imidazo[1,2-a]pyridin-2-one|Smiles: O=C1N=C2C=CC=CN2C1(CC1C=CC=CC=1)CC1C=CC=CC=1|InChiKey: AGKKYNURMHHCFP-UHFFFAOYSA-N|InChi: InChI=1S/C21H18N2O/c24-20-21(15-17-9-3-1-4-10-17,16-18-11-5-2-6-12-18)23-14-8-7-13-19(23)22-20/h1-14H,15-16H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ZSET-845 has no inhibitory action on AChE activity and enhances choline acetyltransferase (ChAT) activity in NB-1 cells.|In Vivo:|Treatment with ZSET-845 at the dose of 0.01, 0.1 and 1 mg/kg significantly ameliorates impaired performance caused by scopolamine.{{Belzutifan} site|{Belzutifan} Metabolic Enzyme/Protease|{Belzutifan} Purity & Documentation|{Belzutifan} In Vivo|{Belzutifan} manufacturer|{Belzutifan} Epigenetic Reader Domain} Oral administration of ZSET-845 causes an increase in ChAT activity in the hippocampus.{{6α-Methylprednisolone 21-hemisuccinate sodium salt} web|{6α-Methylprednisolone 21-hemisuccinate sodium salt} Vitamin D Related/Nuclear Receptor|{6α-Methylprednisolone 21-hemisuccinate sodium salt} Purity & Documentation|{6α-Methylprednisolone 21-hemisuccinate sodium salt} In Vivo|{6α-Methylprednisolone 21-hemisuccinate sodium salt} manufacturer|{6α-Methylprednisolone 21-hemisuccinate sodium salt} Epigenetic Reader Domain} In the hippocampus, ZSET-845 (0.PMID:32009348 01, 0.1 or 1 mg/kg) significantly increases ChAT activity (112%, 113.8% or 108.7%, respectively) compared with matched vehicle-injected control rats. Oral administration of ZSET845 at a dose of 1 or 10 mg/kg ameliorates learning impairment in passive avoidance task and enhanced ChAT activity in the basal forebrain, medial septum and hippocampus, and increases in the number of ChAT-immunoreactive cells in the medial septum in Ab-treated rats to the levels of vehicle-injected control rats.|Products are for research use only. Not for human use.|
